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It gives me great pleasure to 
present this statistical report 
which represents a quarter of 
a century of data collection, 
from 1982 until 2007, from 
the Queensland Centre for 
Gynaecological Cancer (QCGC), 
located at Royal Brisbane and 
Women’s Hospital and Mater 
Hospital, Brisbane, Australia.
The centre started in 1982 as the 
Gynaecological Cancer Unit at Royal 
Women’s Hospital, Brisbane, providing 
services to women with genital tract 
cancer who were referred to the hospital. 
Its first director of services was Dr MJ 
Webb who had moved from the Mayo 
Clinic in Rochester, USA, in the early 
1980s. 
In 1993, following my appointment as the 
new Director of Gynaecological Oncology, 
the QCGC was established as the centre 
responsible to Queensland Health for 
the provision of gynaecological cancer 
services in the state of Queensland.
Over the last 14 years the centre has 
grown from a fledgling clinical service 
with one certified gynaecological 
oncologist and one clinical fellow, to 
the largest such service in Australia with 
six certified gynaecological oncologists, 
three clinical fellows, and at least one 
research fellow, and seeing over 2000 
new patients a year (92 percent of 
Queensland’s gynaecological cancer 
cases).
The centre now runs active training, 
teaching and research programs that 
attract trainee applications from within 
Australia and all around the world.
To date we have had trainees from the 
United Kingdom, Europe, Asia and South 
America, with North America being the 
only unrepresented region.
The QCGC is heavily surgically-oriented 
and provides what is arguably the most 
extensive, comprehensive and intensive 
training in surgical oncology in Australia.
This report is the culmination of over a 
year’s work in compiling and analysing 
prospectively collected data from 
patients’ management, and would not 
have been possible but for the dedication 
and hard work of the gynaecological 
oncologists who work under its banner.
The QCGC has the largest and most 
detailed gynaecological cancer database 
of records in Australia, and quite possibly 
the world. Perusal of these reports shows 
survival curves out to 192 months, or 16 
years. Mr Jackson collated the data and 
edited this report, Mr Tripcony performed 
detailed statistical analyses, and Dr 
Kondalsamy-Chennakesavan helped in 
interpreting and discussing the findings. I 
can’t remember seeing such figures from 
anywhere else in the world.
This of course provides invaluable 
information not only on standard five-year 
survival and median survival but also on 
long term survival.
The database software used, the clinical 
administration system or CAS from 
Mirrabooka Systems Pty Ltd (http://www.
mirrabooka.com/cas.shtml) has provided 
the means to accumulate this extensive 
and detailed collection of data.
A number of interesting and pleasing 
findings have come out of this analysis, 
and I would like to address a couple of 
these cases.
For each site we have compared the 
outcomes for two nine-year periods, 
1984-1993 and 1994-2003. It is pleasing 
to see that for ovarian and uterine cancer 
the outcome in terms of survival has 
improved significantly with time. The 
analysis of ovarian cancer showed some 
very interesting results.
The amount of residual disease left at 
the end of cytoreductive surgery was a 
very powerful determinant of survival, 
second only to disease stage. The results 
presented here are in respect to all stages 
of ovarian cancer.
It was realised that nil residuum would do 
extremely well because it would contain 
all of the stage I and stage II cases. 
However, this has also been shown to be 
the case for stage IIIC ovarian cancer; it 
seems that with stage IIIC of the disease, 
unless residual disease is reduced to 
less than one centimetre, there is little 
beneficial effect on survival.
These figures are not presented here as 
they will be the subject of a separate 
scientific publication, however, it does 
suggest that to date we have been too 
conservative in our approach to ovarian 
cancer surgery.
While we have been good at 
debulking surgery, we need to move 
to cytoreductive surgery, if necessary 
employing peritonectomy type operations 
in selected patients. The figures will 
otherwise be left to speak for themselves.
Prof Alex J Crandon 
Director of Queensland Centre for 
Gynaecological Cancer
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Figure 1: Queensland Centre for Gynaecological Cancer total workload 1982-2006
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Figure 2: Gynaecological cancer incidence 1982-2006
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Figure 3: Cervical cancer incidence 1982-2006
0
50
100
150
200
250
1982 1984 1986 1988 1990 1992 1994 1996 1998 2000 2002 2004 2006
Year
Ca
se
s
Queensland Cancer Registry
Queensland Centre for Gynaecological Cancer
Figure 4: Uterine cancer incidence 1982-2006
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Figure 5: Ovarian cancer incidence 1982-2006
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Figure 6: Vulval cancer incidence 1982-2006
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Figure 7: Vaginal cancer incidence 1982-2006
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Figure 8: Fallopian tube cancer incidence 1982-2006
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Figure 9: Hysterectomy
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Figure 10: Salpingo-oophorectomy
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Figure 11: Lymphadenectomy
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Figure 12: Vaginal surgery
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Figure 13: Gastrointestinal surgery
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Interpretation of results
The preceding section (pages 4-7) shows trends in QCGC’s workload and the incidence data on all major gynaecological malignancies 
between 1982 and 2006. Figure 1 shows a gradual increase in the numbers of patients treated at QCGC from 1982 to 1995. The increase 
in workload is more dramatic between 2002 and 2006. Such an increase in workload could possibly be because of the improved survival 
of patients treated for gynaecological malignancies along with a steady increase in the incidence of gynaecological cancers during this 
period.
Figure 2 shows the incidence of gynaecological cancers from 1982 to 2006. We have presented incidence data from our QCGC database 
and compared it with the incidence data reported by the Queensland Cancer Registry (QCR). Both show a gradual increase in the incidence 
of gynaecological malignancies over this time period. 
Figures 3 to 8 show the incidence data on all major gynaecological malignancies from 1982 to 2006. The incidence of all gynaecological 
malignancies shows an increasing trend with the exception of cervical cancer. Decrease in the incidence of cervical cancer can partially be 
attributed to successful screening and management programs. 
Figures 9 to 13 show the numbers of surgical procedures performed at QCGC between 1996 and 2006. Hysterectomy and salpingo-
oophorectomy were the most common major surgical procedures performed. 
The rest of the report provides detailed statistics on outcomes of major gynaecological cancers.
Statistical analysis
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Outcome statistics on mortality 
ultimately shape the treatment 
given to patients. They also 
serve as a comparison with other 
oncology centres and provide 
effective feedback to clinicians 
working in the field.
Survival analysis is concerned with 
measuring the risk of occurrence of an 
outcome event as a function of time. The 
duration of time is calculated from the 
date of diagnosis until the event occurs 
and uses the survival curve to describe 
its distribution. Therefore, the outcome 
variable of interest is time until an event 
occurs.
In this report, the end point for the 
survival curves is disease-specific death. 
Time is measured in months and is 
calculated by subtracting the date last 
seen from the date of diagnosis.
Median survival can be considered to 
be the expectation of life. When the 
probability of survival reaches 50%, the 
corresponding time value on the X-axis is 
the median survival time.
Relapse-free survival is calculated from 
the date of diagnosis to the time of first 
local/distant failure or date last seen if 
there is no event. If the patient dies due 
to the cancer and there is no recorded 
relapse date then the date of death is 
taken to be the date of relapse.
Deaths are defined as an event if the 
patient died:
Due to cancer
Resulting from treatment
Unknown cause.
Survival data is censored for the following 
reasons:
Withdrawals from study (patient lost 
to follow-up) 
An intervening event (intercurrent 
death)
Discharged after at least a 10 year 
period.
The Kaplan-Meier survival curve estimate 
is obtained by multiplying together 
the proportions of survivors up to and 
including the given failure time. The curve 
remains horizontal between each failure 
time.
A 95% confidence interval is calculated 
and plotted for each group estimate; 
patients at risk and median survival are 
displayed under the graph.
Survival curves are calculated for specific 
time periods. In this report time periods 
of 60 months/five years, 120 months/10 
years and 192 months/16 years are used 
depending on the length of follow-up. 
The numbers displayed on each curve 
represent the following information. 
Likewise, salvage survival is defined 
as the period of time from the date of 
recurrence to the date last seen or date 
of death.
1.
2.
3.
1.
2.
3.
For example, A% (B-C)
A= Percent survival
B= Number in group at risk at the start
C= Number in group remaining due to 
events and censoring.
An in-series patient means primary 
management at or by the QCGC. A 
non in-series patient refers to primary 
management carried out elsewhere 
and these have been excluded from the 
analysis.
A Cox proportional hazards model is 
applied to evaluate the independent 
significance of prognostic factors such as 
age, FIGO stage, histology, differentiation 
and presentation period. Univariate and 
multivariate tables are constructed for 
both relapse free and disease specific 
end points at the various gynaecological 
sites.
In the multivariate tables, hazard or 
relative risk is the ratio of events between 
groups. Therefore a hazard of 1.0 means 
no difference between groups.
Cervical cancer
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Table 1: Patient characteristics
Presentation period 1984-2003 (N=2903)
1984-1993 1994-2003
Factor N=1428 (%) N=1475 (%) p-value
FIGO stage I 889 (62) 976 (66)
II 282 (20) 257 (17)
III 203 (14) 187 (13) 0.16
IV 52 (4) 54 (4)
Unknown 2 (0) 1 (0)
Morphology SCC 1127 (79) 1085 (74)
AdenoCa 220 (15) 286 (19)
AdenoSq 80 (6) 99 (7) 0.004**
Other 1 (0) 5 (0)
Differentiation Well 182 (13) 254 (17)
Moderate 629 (44) 583 (40)
Poor 377 (26) 374 (25) 0.003**
Other/unknown 240 (17) 264 (18)
Age (years) <30 86 (6) 101 (7)
30-39 329 (23) 359 (24)
40-49 314 (22) 364 (25)
50-59 215 (15) 236 (16) 0.02*
60-69 245 (17) 195 (13)
70-79 169 (12) 143 (10)
80+ 70 (5) 77 (5)
Treatment modality Sx alone 587 (41) 655 (44)
RT alone 366 (26) 282 (19)
C alone 4 (0) 4 (0)
Sx+RT 358 (25) 208 (14)
RT+C 30 (2) 162 (11)
Sx+C 9 (1) 7 (1) <0.001**
Sx+RT+C 60 (4) 134 (9)
Other 14 (1) 23 (2)
Cervical cancer
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Table 2: Kaplan and Meier disease specific survival (DSS) estimates and 95% confidence intervals
Presentation period 1984-2003.
E.g. (5/10/16) year (DSS) estimate x% [95% CI]
Period 1984-1993 1994-2003
5 year 71.9 [69.5,74.3] 75.8 [73.3,78.3]
10 year 70.0 [65.4,70.5] 72.6 [69.6,75.6]
16 year 66.3 [63.6,69.0] n/a
FIGO stage I II III IV
5 year 87.9 [86.3,89.5] 63.9 [59.4,68.5] 29.9 [24.6,35.2] 10.7 [4.4,17.1]
10 year 84.2 [82.2,86.2] 58.7 [53.7,63.7] 25.7 [20.2,31.1] –
16 year 82.2 [79.8,84.7] 57.9 [52.7,63.0] 23.3 [17.5,29.2] –
Morphology SCC AdenoCa AdenoSq
5 year 73.5 [71.5,75.5] 81.1 [77.4,84.8] 54.7 [46.9,62.5]
10 year 70.0 [67.8,72.1] 75.4 [71.0,80.0] 52.2 [44.0,60.4]
16 year 68.2 [65.7,70.7] 73.3 [68.3,78.3] –
Differentiation Well Moderate Poor Other
5 year 89.6 [86.5,92.6] 73.1 [70.5,75.8] 60.6 [56.8,64.4] 80.1 [76.2,83.9]
10 year 88.2 [84.9,91.6] 67.9 [64.8,70.9] 56.7 [52.7,60.8] 77.9 [73.7,82.1]
16 year 86.4 [82.3,90.5] 66.8 [63.5,70.0] 54.4 [49.5,59.2] 75.7 [70.9,80.4]
Age (years) <30 30-39 40-59 60+
5 year 77.3 [70.8,83.9] 81.6 [78.5,84.7] 76.2 [73.6,78.9] 63.2 [59.7,66.6]
10 year – 79.3 [76.0,82.7] 72.2 [69.2,75.2] 57.3 [53.4,61.2]
16 year – 78.9 [75.4,82.3] 70.4 [67.0,73.9] 53.9 [49.2,58.5]
Treatment RT alone Sx alone Sx+RT RT+C Sx+RT+C
5 year 47.1[42.9,51.4] 95.1[93.8,96.4] 69.8[65.8,73.7] 47.7[38.4,57.1] 61.0[52.9,69.1]
10 year 41.8[37.2,46.4] 92.4[90.7,94.2] 64.2[59.8,68.5] – 55.7[46.1,65.2]
16 year 37.1[31.6,42.6] 91.6[89.7,93.6] 62.4 [57.4,67.4] – 55.7[46.1,65.2]
Cervical cancer
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Table 3: Univariate Cox model
Presentation period 1984-2003.
DSS RFS
Factor Hazard [95% CI] p-value Hazard [95% CI] p-value
Stage
I vs II 3.16 [2.6,3.8] 0.0** 2.89 [2.42,3.45] 0.0**
III 8.97 [7.5,10.8] 0.0** 7.06 [6.0,8.4] 0.0**
IV 21.98 [17.4,28.2] 0.0** 15.9 [12.5,20.3] 0.0**
Morphology
SCC vs AdenoCa 0.74 [0.6,0.9] 0.006** 0.79 [0.7,1.0] 0.02*
AdenoSq 1.87 [1.5,2.4] 0.0** 1.86 [1.5,2.3] 0.0**
Other 1.68 [0.2,12.0 0.6 1.19 [0.2,8.5] 0.86
Period
1984-1993 vs 1994-2003 0.85 [.7,1.0] 0.03* 0.86 [0.8,1.0] 0.03*
Differentiation
Well vs Moderate 2.83 [2.1,3.9] 0.0** 2.47 [1.9,3.2] 0.0**
Poor 4.53 [3.3,6.2] 0.0** 3.82 [2.9,5.0] 0.0**
Other 1.97 [1.38,2.8] <0.001** 1.6 [1.2,2.2] 0.004**
Age
40-59 years vs <30 0.82 [0.6,1.2] 0.27 0.79 [0.6,1.1] 0.15
30-39 0.72 [0.6,0.9] 0.002** 0.69 [0.6,0.8] <0.001**
60+ 1.68 [1.4,2.0] 0.0** 1.55 [1.3,1.8] <0.001**
Treatment
RT vs Sx 0.08 [0.06,0.1] 0.0** 0.11 [0.09,0.14] 0.0**
RT+Sx 0.45 [0.38,0.5] 0.0** 0.51 [0.43,0.61] 0.0**
RT+C 0.97 [0.7,1.3] 0.83 0.99 [0.78,1.26] 0.94
Sx+RT+C 0.59 [0.45,0.78] <0.001** 0.67 [0.52,0.85] <0.001**
Other 1.89 [1.34,2.66] <0.001** 1.73 [1.24,2.44] <0.001**
Cervical cancer
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Table 4: Multivariate Cox model
Presentation period 1984-2003.
DSS RFS
Factor Hazard [95% CI] p-value Hazard [95% CI] p-value
Stage
I vs II 1.58 [1.27,1.97] <0.001** 1.55 [1.26,1.9] <0.001**
III 3.93 [3.11,4.97] 0.0** 3.41 [2.73,4.27] <0.001**
IV 9.31 [6.99,12.4] 0.0** 6.89 [5.23,9.07] <0.001**
Morphology
SCC vs AdenoCa 1.24 [0.99,1.54] 0.06 1.24 [1.02,1.52] 0.03
AdenoSq 1.59 [1.24,2.04] <0.001** 1.64 [1.29,2.08] <0.001**
Other 4.46 [0.62,32.1] 0.14 2.99 [0.42,21.4] 0.28
Period
1984-1993 vs 1994-2003 0.91 [0.78,1.06] 0.22 0.91 [0.79,1.05] 0.21
Differentiation
Well vs Moderate 1.62 [1.18,2.22] 0.003** 1.46 [1.11,1.93] 0.008**
Poor 2.1 [1.52,2.89] <0.001** 1.8 [1.36,2.4] <0.001**
Other 1.14 [0.79,1.63] 0.5 0.93 [0.67,1.29] 0.67
Age
40-59 years vs <30 1.55 [1.09,2.2] 0.02* 1.3 [0.94,1.81] 0.12
30-39 1.19 [0.96,1.48] 0.12 1.06 [0.86,1.29] 0.6
60+ 1.07 [0.89,1.28] 0.47 1.01 [0.86,1.2] 0.87
Treatment
RT vs Sx 0.19 [0.14,0.26] 0.0** 0.25 [0.19,0.34] <0.001**
RT+Sx 0.81 [0.65,1.01] 0.06 0.85 [0.69,1.05] 0.14
RT+C 0.89 [0.68,1.17] 0.4 0.93 [0.72,1.2] 0.58
Sx+RT+C 0.85 [0.63,1.13] 0.26 0.92 [0.7,1.21] 0.54
Other 2.22 [1.54,3.21] <0.001** 2.17 [1.5,3.12] <0.001**
Cervical cancer
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Figure 14: Overall survival 1984-2003 by FIGO stage
100
 90
 80
 70
 60
 50
 40
 30
 20
 10
  0
%
 s
ur
vi
va
l
 32  64  96 128 160 192
Months
68% (2903-132) All
 All 2903 1852 1300  919  569  294  132  66,  70[  ]
82% (1865-99) S1
S1 1865 1418 1038  745  459  230   99  80,  84[  ]
58% (539-27) S2
S2  539  305  198  132   82   48   27  53,  63[  ]
23% (390-4) S3
S3  390  115   55   36   23   13    4  17,  29[  ]
11% (106-2) S4
   95% Cl
S4  106   12    8    5    4    2    2   4,  17[  ]
Median
23 months
9 months
Figure 15: Relapse free survival 1984-2003 by FIGO stage
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Figure 16: Overall survival 1984-2003 FIGO stage I by age
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Figure 17: Overall survival 1984-2003 FIGO stage II-IV by age
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Figure 18: Overall survival 1984-1993 by FIGO stage
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Figure 19: Overall survival 1994-2003 by FIGO stage
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Figure 20: Relapse free survival 1984-1993 by FIGO stage
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Figure 21: Relapse free survival 1994-2003 by FIGO stage
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Figure 22: Salvage survival 1984-2003 by site of relapse
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Figure 23: Salvage survival 1984-2003 by treatment type for relapse
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Interpretation of results
Table 1 shows the key characteristics of all patients who were treated for cervical cancer at QCGC. We have grouped patients into 
two categories based on the year in which they presented (1984 to 1993 and 1994 to 2003). It is interesting to note that all the key 
characteristics (tumour morphology, differentiation and treatment modality) differed between these two groups, with the exception of FIGO 
staging.
Table 2 shows disease specific survival estimates (five, 10 and 16 years) and 95% confidence intervals, by key characteristics. The five-year 
survival rates achieved at QCGC is significantly better than the survival rates reported by FIGO in their latest report (Volume 26).  
Tables 3 and 4 show univariate and multivariate Cox proportional hazards models respectively, evaluating the significance of prognostic 
factors such as age, FIGO stage, treatment time-period, morphology, grade and treatment modality. Univariate analyses (Table 3) showed 
significant decline in their risk if they presented between 1994 and 2003 when compared to the previous time-period (1984 to 1993). 
However, this statistical significance did not persist in our multivariate model (Table 4). 
Figures 14 and 15 show overall and relapse-free survival between 1984 and 2003, by FIGO stages. Overall survival (95% CI) and relapse-free 
survival (95% CI) at 192 months was 68% (66-70%) and 65% (63-67%) respectively. Figures 16 and 17 show the influence of age categories 
(<50 years and > 50 years) on overall survival by FIGO stages. Figures 18 to 21 show overall and relapse-free survival at five years, by FIGO 
stage. These results achieved seem to be better than the results published by FIGO in their triennial report. Figure 22 shows the outcomes 
of salvage survival by site of relapse. Figure 23 shows the outcomes of salvage survival by treatment type for relapse. With the exception of 
few case reports and case series, published literature on salvage survival for cervical cancer is negligible and formal comparisons can not 
be made at this point in time.
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Table 5: Patient characteristics
Presentation period 1984-2003 (N=2119)
1984-1993 1984-1993
Factor N=834 (%) N=1286 (%) p-value
FIGO stage I 221 (26) 406 (32)
II 95 (11) 113 (9) 0.59
III 423 (51) 648 (50)
IV 3 (1) 5 (0)
Unknown
Morphology Ser/PapSer 337 (40) 526 (41)
AdenoCa 75 (9) 60 (5)
Endometriod 102 (12) 132 (10)
Mucinous 70 (8) 157 (12) <0.001**
Mull+Meso 23 (3) 38 (3)
Clear cell 140 (17) 152 (12)
Other 20 (2) 7 (1)
Differentiation Well 91 (11) 129 (10)
Moderate 186 (22) 246 (19)
Poor 299 (36) 569 (44) 0.02*
Other/unknown 258 (31) 342 (27)
Age (years) <30 54 (6) 62 (5)
30-39 43 (5) 89 (7)
40-49 134 (16) 182 (14)
50-59 198 (24) 342 (27) <0.001**
60-69 238 (29) 289 (23)
70-79 137 (16) 246 (19)
80+ 30 (4) 76 (6)
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1984-1993 1984-1993
Factor N=834 (%) N=1286 (%) p-value
Treatment modality Sx alone 149 (18) 297 (23)
RT alone 1 (0) 0 (0)
C alone 11 (1) 9 (1)
Sx+RT 21 (3) 3 (0)
RT+C 1 (0) 0 (0) <0.001**
Sx+C 611 (73) 958 (75)
Sx+RT+C 32 (4) 11 (11)
Other 8 (1) 8 (1)
Ovarian cancer
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Table 6: Kaplan and Meier disease specific survival (DSS) estimates and 95% confidence intervals
Presentation period 1984-2003.
E.g. (5/10/16) year (DSS) estimate x% [95% CI].
Period 1984-1993 1994-2003
5 year 46.9[43.4,50.4] 53.4[50.1,56.8]
10 year 37.9[34.4,41.3] 39.7[33.6,45.8]
16 year 34.8[31.2,38.4] –
FIGO stage I II III IV
5 year 88.9[86.2,91.6] 65.1[57.8,72.4] 32.6[29.3,35.9] 12.4[6.8,17.9]
10 year 82.9[79.2,86.6] 53.2[44.4,62.0] 18.4[15.1,21.7] 5.5[0,10.4]
16 year 81.1[76.9,85.3] 49.0[39.1,58.9] 15.1[11.5,18.6] n/a
Morphology Ser/PapSer AdenoCa Endometrioid Mucinous
5 year 37.5[33.9,41.1] 29.8[20.8,38.8] 66.7[59.9,73.5] 74.8[68.7,80.8]
10 year 25.5[21.7,29.3] 17.7[8.9,26.5] 57.2[49.4,65.0] 68.6[61.0,76.3]
16 year 22.2[18.1,26.4] 14.7[5.6,23.8] 55.2[46.8,63.7] –
Morphology Mull+Meso Clear cell Other
5 year 27.4[14.9,39.8] 59.9[52.1,67.6] 69.7[64.3,75.2]
10 year 10.1[0.0,21.2] 50.6[41.7,59.6] 61.0[54.1,67.5]
16 year – 46.2[36.2,56.3] 56.4[48.5,64.4]
Differentiation Well Moderate Poor Other
5 year 86.7[81.9,91.5] 51.7[46.5,57.0] 35.8[32.0,39.6] 57.4[53.1,61.8]
10 year 79.8[73.1,86.5] 40.5[34.6,46.4] 21.3[17.2,25.5] 49.8[45.0,54.6]
16 year 68.3[57.8,78.9] 36.9[30.3,43.6] 19.7[15.3,24.1] 48.7[43.7,53.6]
Age (years) 40 40-59 60+
5 year 77.0[71.3,82.6] 53.7[50.0,57.5] 42.1[38.5,45.6]
10 year 74.1[67.8,80.4] 43.8[39.7,47.9] 28.5[24.5,32.4]
16 year 71.4[64.4,78.5] 40.3[35.7,45.0] 25.0[20.3,29.7]
Treatment Sx alone Sx+C Sx+RT+C
5 year 78.8[74.7,83.0] 45.3[42.5,48.1] 33.6[19.3,48.0]
10 year 74.0[68.7,79.0] 34.3[31.2,37.3] 15.2[3.8,26.5]
16 year – 30.4[27.0,33.9] 11.4[1.0,22.1]
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Table 7: Univariate Cox model
Presentation period 1984-2003.
Factor DSS RFS
Hazard [95% CI] p-value Hazard [95% CI] p-value
Stage
I vs II 3.42 [2.5,4.69] <0.001** 4.0 [3.04,5.26] <0.001**
III 8.8 [6.99,11.1] <0.001** 9.42 [7.65,11.6] <0.001**
IV 17.94 [13.7,23.5] <0.001** 14.6 [11.4,18.7] <0.001**
Morphology
Ser/PapSer vs AdenoCa 1.43 [1.14,1.79] <0.001** 1.25 [1.01,1.54] 0.04*
Endometroid 0.44 [0.34,0.56] <0.001** 0.42 [0.34,0.51] <0.001**
Mucinous 0.34 [0.26,0.45] <0.001** 0.28 [0.21,0.36]  <0.001**
Mull+Meso 1.83 [1.35,2.48] <0.001** 1.53 [1.15,2.03] 0.003**
Clear cell 0.59 [0.47,0.76] <0.001** 0.49 [0.39,0.62] <0.001**
Period 
1984-1993 vs 1994-2003 0.78 [0.68,0.88] <0.001** 0.81 [0.72,0.91] <0.001**
Differentiation
Well vs Moderate 3.64 [2.6,5.1] <0.001** 3.22 [2.4,4.3] <0.001**
Poor 5.33 [3.86,7.35] <0.001** 4.76 [3.6,6.3] <0.001**
Other 3.06 [2.2,4.27] <0.001** 2.57 [1.9,3.4] <0.001**
Age
40-59 years vs <40 years 0.43 [0.32,0.56] <0.001** 0.44 [0.35,0.57] <0.001**
60+years 1.47 [1.29,1.67] <0.001** 1.37 [1.22,1.54] <0.001**
Treatment
Sx vs Sx+C 2.88 [2.32,3.58] <0.001** 3.42 [2.79,4.2] <0.001**
Sx+RT+C 4.27 [2.9,6.3] <0.001** 4.54 [3.12,6.54] <0.001**
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Table 8: Multivariate Cox model
Presentation period 1984-2003.
Factor DSS RFS
Hazard [95% CI] p-value Hazard [95% CI] p-value
Stage
I vs II 4.35 [3.07,6.17] <0.001** 4.26 [3.14,5.78] <0.001**
III 11.58 [8.64,15.5] <0.001** 9.65 [7.44,12.5] <0.001**
IV 21.4 [15.3,29.7] <0.001** 13.82 [10.2,18.6] <0.001**
Morphology
Ser/PapSer vs AdenoCa 1.08 [0.86,1.37] <0.001** 1.02 [0.82,1.26] 0.87
Endometrioid 0.8 [0.62,1.02] 0.07 0.72 [0.58,0.9] 0.003*
Mucinous 1.41 [1.05,1.89] 0.02* 1.1 [0.83,1.44] 0.5
Mul+Mes 1.76 [1.3,2.4] <0.001** 1.59 [1.19,2.12] <0.001**
Clear cell 1.59 [1.23,2.05] <0.001** 1.26 [0.99,1.61] 0.06
Period
1984-1993 vs 1994-2003 0.74 [0.65,0.85] <0.001** 0.8 [0.71,0.91] <0.001**
Differentiation
Well vs Moderate 2.46 [1.75,3.47] <0.001** 2.03 [1.51,2.73] <0.001**
Poor 2.73 [1.95,3.81] <0.001** 2.2 [1.65,2.93] <0.001**
Other 2.61 [1.86,3.66] <0.001** 1.99 [1.48,2.67] <0.001**
Age
40-59 years vs <40 years 0.74 [0.55,0.98] 0.04* 0.73 [0.57,0.95] 0.02*
60+years 1.34 [1.17,1.53] <0.001** 1.24 [1.1,1.4] <0.001**
Treatment
Sx vs Sx+C 0.51 [0.39,0.66] 0.006** 0.68 [0.54,0.87] <0.001**
Sx+RT+C 0.56 [0.37,0.85] <0.001** 0.70 [0.47,1.05] 0.09
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Figure 24: Overall survival 1984-2003 by FIGO stage
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Figure 25: Relapse free survival 1984-2003 by FIGO stage
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Figure 26: Overall survival 1984-2003 by presentation period
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Figure 27: Relapse free survival 1984-2003 by presentation period
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Figure 28: Overall survival 1984-1993 by FIGO stage
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Figure 29: Overall survival 1994-2003 by FIGO stage
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Figure 30: Relapse free survival 1984-1993 by FIGO stage
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Figure 31: Relapse free survival 1994-2003 by FIGO stage
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Figure 32: Salvage survival 1984-2003 by site of relapse
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Figure 33: Salvage survival 1984-2003 by treatment type for relapse
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Interpretation of results
Table 5 shows the key characteristics of patients diagnosed with ovarian cancer by presentation period. With the exception of FIGO 
staging, all the key characteristics (age, morphology, grade and treatment modality) differed significantly between these two time periods. 
Table 6 shows disease specific survival estimates (five, 10 and 16 years) and 95% confidence intervals, by key characteristics. The five-
year survival rate achieved at QCGC for malignant ovarian tumours is better than the survival rates reported by FIGO in their latest report 
(volume 26).
Tables 7 and 8 show univariate and multivariate Cox proportional hazards models respectively, evaluating the significance of prognostic 
factors such as age, FIGO stage, treatment time-period, morphology, grade and treatment modality. Univariate analyses (Table 7) showed 
significant decline in their risk if they presented between the years 1994-2003 when compared to the previous time-period (1984 to 1993). 
This statistical significance persisted in our multivariate model (Table 4) after adjusting for other key prognostic factors. It is possible that 
availability of better chemotherapeutic regimens and newer drugs in the recent presentation period could have resulted in significant 
improvements when compared to the previous presentation period. 
Figures 24 and 25 show overall and relapse-free survival between 1984 and 2003, by FIGO stages. Overall survival (95% CI) and relapse-
free survival (95% CI) at 16 years was 37% (34-40%) and 34% (31-36%) respectively. Figures 26 and 27 show overall and relapse-free 
survival at five years by presentation period. These survival curves show significant improvement in the recent presentation period 
compared to the previous presentation period. Figure 28 shows 47% overall survival at five years for the time period 1984 to 1993. Overall 
survival at five years was 53% for the time period 1994 to 2003 (Figure 29). Between 1984 and 1993, the relapse-free survival rate was 35% 
at five years (Figure 30). In the recent time period (1994 to 2003), the relapse-free survival at five years has improved to 42% (Figure 31). 
Figures 32 and 33 show five-year salvage survival curves for ovarian cancer. Between 1982 and 2003, the overall salvage survival (95% CI) 
at five years was 13% (10-15%). There is a paucity of information on salvage survival for ovarian cancer in the published literature and no 
reasonable comparisons can be made.
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Table 9: Patient characteristics
Presentation period 1984-2003 (N=52)
1984-1993 1994-2003
Factor N=18 (%) N=34 (%) p-value
FIGO stage I 8 (44) 11 (32)
II 3 (17) 11 (32) 0.56
III 7 (39) 12 (35)
IV 0 (0) 0 (0)
Unknown 0 (0) 0 (0)
Morphology AdenoCa 7 (39) 5 (15)
PapSer 4 (22) 15 (44) 0.1
Other 7 (39) 14 (41)
Differentiation Well 0 (0) 0 (0)
Moderate 6 (33) 7 (21) 0.02*
Poor 5 (28) 23 (68)
Other/unknown 7 (39) 4 (12)
Age (years) <30 0 (0) 0 (0)
30-39 0 (0) 2 (6)
40-49 4 (22) 7 (21) 0.75
50-59 6 (33) 9 (26)
60-69 5 (28) 7 (21)
70-79 2 (11) 8 (23)
80+ 1 (1) 1 (3)
Treatment modality Sx alone 2 (11) 3 (9)
RT alone 0 (0) 0 (0)
C alone 0 (0) 0 (0)
Sx+RT 1 (6) 0 (0) 0.13
RT+C 0 (0) 0 (0)
Sx+C 11 (61) 29 (85)
Sx+RT+C 4 (22) 2 (6)
Other 0 (0) 0 (0)
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Table 10: Kaplan and Meier disease specific survival (DSS) estimates and 95% confidence intervals
Presentation period 1984-2003.
E.g. Five year (DSS) estimate x% [95% CI].
Period 1984-1993 1994-2003
5 year 71.1 [49.7,92.5] 63.7 [37.3,90.0]
FIGO stage I II III IV
5 year 68.0 [44.7,91.3] 78.6 [51.3,100] 72.0 [48.1,95.8] n/a
Morphology AdenoCa PapSer Other
5 year 65.5 [32.8,98.1] 54.3 [19.,89.6] 79.5 [58.3,100]
Differentiation Well Moderate Poor Other
5 year N/A 80.7 [56.1,100] 66.3 [41.2,91.5] 62.3 [32.9,91.7]
Age ( years ) <50 >=50
5 year 74.1 [42.5,100] 67.6 [49.4,85.9]
Treatment Sx+C Sx+RT+C
5 year 68.1 [48.6,87.5] 50 [10.0,90.0]
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Table 11: Univariate Cox model
Presentation period 1984-2003.
Factor DSS RFS
Hazard [95% CI] p-value Hazard [95% CI] p-value
Stage
I vs II 1.89 [0.51,7.09] 0.34 2.25 [0.72,7.02] 0.16
III 1.96 [0.59,6.52] 0.27 4.21 [1.58,11.2] 0.004**
Morphology
AdenoCa vs PapSer 1.07 [0.28,4.05] 0.92 1.49 [0.52,4.3] 0.46
Other 0.82 [0.23,2.92] 0.76 0.99 [0.34,2.91] 0.99
Period
1984-1993 vs 1994-2003 0.85 [0.28,2.61] 0.77 0.81 [0.37,1.76] 0.59
Differentiation
Well vs Moderate 0.34 [0.07,1.7] 0.19 0.34 [0.09,1.3] 0.11
Poor 0.89 [0.29,2.71] 0.83 1.3 [0.53,3.23] 0.57
Age
<50 years vs 50+ 2.5 [0.56,11.1] 0.23 2.97 [0.89,9.89] 0.08
Treatment
Sx+C vs Sx+C+RT 1.97 [0.66,5.86] 0.23 1.07 [0.4,2.86] 0.9
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Table 12: Multivariate Cox model
Presentation period 1984-2003.
Factor DSS RFS
Hazard [95% CI] p-value Hazard [95% CI] p-value
Stage
I vs II 1.73 [0.38,7.89] 0.48 1.57 [0.47,5.28] 0.46
III 1.52 [0.39,5.9] 0.54 3.05 [1.03,9.05] 0.04*
Morphology
AdenoCa vs PapSer 0.7 [0.11,4.33] 0.7 0.94 [0.25,3.57] 0.93
Other 0.15 [0.01,1.84] 0.14 0.62 [0.13,2.97] 0.55
Period
1984-1993 vs 1994-2003 1.49 [0.25,8.99] 0.67 0.99 [0.3,3.31] 0.99
Differentiation
Well vs Moderate 0.53 [0.09,3.18] 0.49 0.54 [0.11,2.65] 0.45
Poor 1.37 [0.27,6.85] 0.7 1.75 [0.45,6.76] 0.42
Age
<50 years vs 50+ 1.55 [0.28,8.47] 0.62 2.31 [0.63,8.5] 0.2
Treatment
Sx+C vs Sx+C+RT 11.2 [0.86,145.] 0.07 2.75 [0.47,16.1] 0.26
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Figure 34: Overall survival 1984-2003 by FIGO stage
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Figure 35: Relapse free survival 1984-2003 by FIGO stage
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Figure 36: Overall survival 1984-2003 by presentation period
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Figure 37: Relapse free survival 1984-2003 by presentation period
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Figure 38: Overall survival 1984-1993 by FIGO stage
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Figure 39: Overall survival 1994-2003 by FIGO stage
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Figure 40: Relapse free survival 1984-1993 by FIGO stage
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Figure 41: Relapse free survival 1994-2003 by FIGO stage
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Figure 42: Salvage survival 1984-2003 by type of relapse
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Figure 43: Salvage survival 1984-2003 by treatment type for relapse
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Interpretation of results
Table 9 shows key characteristics of patients diagnosed with fallopian tube cancer by presentation period. Eighteen patients were 
diagnosed with fallopian tube cancer between 1984 and 1993, and 34 were diagnosed with fallopian tube cancer between 1994 and 
2003. All the key characteristics were similar between these time periods with the exception of tumour grades where the differences 
were statistically significant. Table 10 shows five-year disease specific survival estimates and 95% confidence intervals. Overall five-
year survivals (95% CI) for the presentation periods 1984-1993 and 1994-2003 were 71% (50-92) and 64% (37-90) respectively. These 
differences were not statistically significant. However, these survival rates are better than the reported survival rates from FIGO.
Tables 11 and 12 show univariate and multivariate Cox proportional hazards models respectively, evaluating the significance of prognostic 
factors such as age, FIGO stage, treatment time-period, morphology, grade and treatment modality. 
Figures 34 and 35 show overall and relapse-free survival between 1984 and 2003, by FIGO stages. Overall survival (95% CI) and relapse-
free survival (95% CI) at 16 years was 46% (24-68%) and 36% (18-53%) respectively. Figures 36 and 37 show overall and relapse-free 
survival at five years by presentation period. No statistically significant differences in these survivals can be noticed between the 
presentation periods. Figures 38 to 41 show overall and relapse-free survival at five years by presentation periods and FIGO stages. Figures 
42 and 43 show five-year salvage survival curves. Between 1982 and 2003, the overall salvage survival (95% CI) at five years was 23% (0-
48%).
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Table 13: Patient characteristics
Presentation period 1984-2003 (N=3380)
1984-1993 1994-2003
Factor N=1266 (%) N=2114 (%) p-value
FIGO stage I 998 (79) 1518 (72)
II 85 (7) 178 (8) <0.001**
III 115 (9) 284 (13)
IV 63 (5) 118 (6)
Unknown 5 (0) 16 (1)
Morphology# A 1087 (86) 1740 (82)
B 58(5) 140 (7)
C 42 (3) 93 (4) 0.05*
D 32 (2) 56 (3)
Other 47(4) 85(4)
Differentiation Well 302 (24) 689 (33)
Moderate 307 (24) 739 (35)
Poor 152 (12) 404 (19) 0.43
Other/unknown 505 (40) 282 (13)
Age (years) <30 5 (0) 9 (0)
30-39 18 (1) 42 (2)
40-49 124 (10) 200 (9)
50-59 299 (24) 550 (26) <0.001**
60-69 427 (34) 609 (29)
70-79 320 (25) 504 (24)
80+ 73 (6) 200 (9)
# See page 45.
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1984-1993 1994-2003
Factor N=1266 (%) N=2114 (%) p-value
Treatment modality Sx alone 210 (17) 1172 (55)
RT alone 15 (1) 34 (2)
C alone 4 (0) 3 (0)
Sx+RT 950 (75) 718 (34)
RT+C 2 (0) 4 (0) <0.001**
Sx+C 24 (2) 82 (4)
Sx+RT+C 43 (3) 72 (3)
Other 18 (2) 29 (1)
# Morphology
A AdenoCa
 Papillary
 AdenoSq
 Endometrioid
B Mull
 Meso
 CS
C PapSer
D LMS
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Table 14: Kaplan and Meier disease specific survival (DSS) estimates and 95% confidence intervals
E.g. (5/10/16) year (DSS) estimate x% [95% CI].
Period 1984-1993 1994-2003
5 year 80.5 [78.3,82.7] 84.3 [82.5,86.1]
10 year 77.7 [75.3,80.1] 82.4 [80.3,84.6]
16 year 77.2 [74.7,79.6] n/a
FIGO stage I II III IV
5 year 92.8 [91.7,93.9 82.3 [76.9,87.8] 46.4 [40.5,52.3 10.6 [5.,16.2]
10 year 90.3 [88.9,91.8] 78.8 [72.5,85.] 41.9 [35.3,48.5] 7. [2.1,12.]
16 year 1 73.7 [64.7,82.7] 41.9 [35.3,48.5] 3. [0.,9.0]
Morphology# A B C D
5 year 88.0 [86.6,89.3] 58.9 [50.9,66.8] 38.1 [27.4,48.8] 40.5 [28.,53.1]
10 year 85.6 [84.1,87.2] 51.7 [42.,61.4] 30.6 [19.,42.1] 34.0 [20.6,47.4]
16 year 85.1 [83.4,86.8] – 26.8 [14.5,39.1] –
Differentiation Well Moderate Poor Other
5 year 97.4 [96.3,98.5] 87.9 [85.6,90.2] 54.3 [49.5,59.1] 76.8 [73.7,80.]
10 year 95.7 [94.1,97.4] 83.8[80.7,86.9] 52.1 [47.,57.3] 74.1 [70.8,77.4]
16 year – 83.3 [80.1,86.5] 47.2 [39.1,55.2] –
Age (years) <50 >=50
5 year 89.3 [86.,92.7] 81.8 [80.2,83.3]
10 year 88.0 [84.2,91.6] 78.8 [77.1,80.6]
16 year 87.9 [84.2,91.6] 78.1 [76.2,80.1]
Treatment RT alone Sx alone Sx+RT Sx+C Sx+RT+C
5 year 45.0 [25.3,64.8] 86.3 [84.2,88.4] 87. [85.2,88.7] 43.9 [33.1,54.7] 47.5 [37.,57.9]
10 year – 83.7 [80.9,86.6] 84.2 [82.3,86.2] 37.6 [23.,52.3] 41.2[30.4,52.]
16 year – – 83.7 [81.6,85.8] – 38.0 [26.4,49.6]
# See page 45.
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Table 15: Univariate Cox model
Factor DSS RFS
Hazard [95% CI] p-value Hazard [95% CI] p-value
Stage
I vs II 2.5 [1.81,3.57] <0.001** 2.77 [2.1,3.66] <0.001**
III 9.59 [7.7,11.84] <0.001** 7.78 [6.45,9.4] <0.001**
IV 34.8 [27.6,43.7] <0.001** 24.4 19.8,30.2] <0.001**
Morphology#
A vs B 4.67 [3.6,6.0] <0.001** 4.49 [3.57,5.65] <0.001**
C 6.49 [5.0,8.5] <0.001** 5.85 [4.58,7.46] <0.001**
D 2.99 [2.1,4.2] <0.001** 6.24 [4.68,8.3] <0.001**
Period
1984-1993 vs 1994-2003 0.79 [0.7,0.9] 0.007** 0.87 [0.75,1.02] 0.08
Differentiation
Well vs Moderate 3.96 [2.7,5.9] <0.001** 2.77 [2.04,3.75] <0.001**
Poor 18.0 [12.4,26.2] <0.001** 10.5 [7.87,14.1] <0.001**
Other 7.8 [5.3,11.3]] <0.001** 5.0 [3.7,6.7] <0.001**
Age
<50 years vs >=50 years 1.78 [1.29,2.46] <0.001** 1.6 [1.2,2.1] <0.001**
Treatment
Sx vs RT 4.25 [2.6,6.9] <0.001** 3.74 [2.36,5.93] <0.001**
RT+Sx 0.9 [0.7,1.1] 0.33 0.92 0.77,1.11] 0.38
RT+C 5.7 [4.2,7.9] <0.001** 5.64 [4.25,7.5] <0.001**
Sx+RT+C 4.3 [3.2,5.9] <0.001** 4.08 [3.08,5.4] <0.001**
# See page 45.
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Table 16: Multivariate Cox model
Factor DSS RFS
Hazard [95% CI] p-value Hazard [95% CI] p-value
Stage
I vs II 2.34 [1.6,3.3]] <0.001** 2.62 [1.98,3.48] <0.001**
III 7.97 [6.36,9.99] <0.001** 6.38 [5.2,7.8] <0.001**
IV 19.05 [14.5,25.0] <0.001** 12.7 [9.8,16.3] <0.001**
Morphology#
A vs B 2.37 [1.8,3.2] <0.001** 2.18 [1.68,2.82] <0.001**
C 1.61 [1.18,3.2] <0.001** 1.51 [1.13,2.01] <0.001**
D 3.59 [2.48,5.2] <0.001** 3.7 [2.6,5.2] <0.001**
Period
1984-1993 vs 1994-2003 0.54 [0.45,0.66] <0.001** 0.61 [0.51,0.72] <0.001**
Differentiation
Well vs Moderate 2.66 [1.79,3.95] <0.001** 1.88 [1.38,2.57] <0.001**
Poor 6.8 [4.6,10.1] <0.001** 3.8 [2.8,5.2] <0.001**
Other 4.19 [2.8,6.2] <0.001** 2.8 [2.1,3.8] <0.001**
Age
<50 years vs >=50 years 2.65 [1.86,3.76] <0.001** 2.1 [1.55,2.84] <0.001**
Treatment
Sx vs RT 2.23 [1.35,3.68] 0.002** 1.95 [1.22,3.12] 0.005**
RT+Sx 0.65 [0.52,0.8] <0.001** 0.7 [0.57,0.85] <0.001**
RT+C 0.58 [0.41,0.82] <0.002** 0.81 [0.59,1.12] 0.2
Sx+RT+C 0.56 [0.4,0.79] <0.001** 0.77 [0.56,1.06] 0.11
# See page 45.
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Figure 44: Overall survival 1984-2003 by FIGO stage
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Figure 45: Relapse free survival 1984-2003 by FIGO stage
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Figure 46: Overall survival 1984-2003 by presentation period
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Figure 47: Relapse free survival 1984-2003 by presentation period
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Figure 48: Overall survival 1984-1993 by FIGO stage
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Figure 49: Overall survival 1994-2003 by FIGO stage
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Figure 50: Relapse free 1984-1993 by FIGO stage
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Figure 51: Relapse free 1994-2003 by FIGO stage
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Figure 52: Salvage survival 1984-2003 by site of relapse
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Figure 53: Salvage survival 1984-2003 by treatment type for relapse
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Interpretation of results
Table 13 shows the key characteristics of all those patients who were treated for uterine cancer at QCGC. We have grouped patients 
into two categories based on the year in which they presented (1984 to 1993 and 1994 to 2003). It is interesting to note that all the key 
characteristics (FIGO staging, tumour morphology, and treatment modality) differed between these two groups, with the exception of 
tumour grade/differentiation.
Table 14 shows disease specific survival estimates (five, 10 and 16 years) and 95% confidence intervals, by key characteristics. The five-
year survival rate achieved at QCGC for uterine cancer is better than the survival rates reported by FIGO in their latest report (table 10, 
corpus uteri, volume 26). Tables 15 and 16 show univariate and multivariate Cox proportional hazards models respectively, evaluating the 
significance of prognostic factors such as age, FIGO stage, treatment time-period, morphology, grade and treatment modality. For disease 
specific survival in our multivariate model, it is interesting and important to note that those who presented in the recent time period (1994 
to 2003) had a hazard ratio (95% CI) of 0.54 (0.45-0.66) when compared those presenting in 1984 to 1993. Similar pattern could be noticed 
for relapse-free survival with a hazard ratio (95% CI) of 0.61 (0.51-0.72). 
Figures 44 and 45 show overall and relapse-free survival between 1984 and 2003, by FIGO stages. Overall survival (95% CI) and relapse-
free survival (95% CI) at 192 months/16 years were 79% (78-81%) and 75% (73-77%) respectively. Figures 46 and 47 show overall 
and relapse-free survival at five years by presentation period. The overall survival curves show significant improvement in the recent 
presentation period compared to the previous presentation period. Detailed survival curves on overall and relapse-free survival by FIGO 
stages and presentation period are given in Figures 48-51. Data on salvage survivals for uterine cancer are provided in Figures 52 and 53, 
by site of relapse and by treatment modality, respectively.
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Table 17: Patient characteristics
Presentation period 1984-2003 (N=216)
1984-1993 1994-2003
Factor N=68 (%) N=80 (%) p-value
FIGO stage I 25 (36) 12 (31)
II 17 (25) 27 (34)
III 16 (24) 13 (16) 0.53
IV 10 (15) 11 (14)
Unknown 0 4 (5)
Morphology SCC 58 (85) 60 (75)
AdenoCa 5 (7) 6 (7) 0.18
Other 5 (7) 14 (18)
Differentiation Well 5 (7) 6 (7)
Moderate 15 (22) 23 (29) <0.001**
Poor 11 (16) 33 (41)
Other/unknown 37 (54) 18 (23)
Age (years) <30 2 (3) 1 (0)
30-39 4 (6) 4 (5)
40-49 5 (7) 10 (13)
50-59 10 (15) 15 (19) 0.43
60-69 16 (24) 18 (23)
70-79 22 (32) 15 (19)
80+ 9 (13) 17 (21)
Treatment modality Sx alone 8 (12) 12 (15)
RT alone 37 (54) 30 (38)
C alone 0 (0) 0 (0)
Sx+RT 14 (21) 13 (16)
RT+C 5 (7) 14 (18) 0.11
Sx+C 0 (0) 0 (0)
Sx+RT+C 1 (1) 6 (8)
Other 3 (4) 5 (6)
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Table 18: Kaplan and Meier disease specific survival (DSS) estimates and 95% confidence intervals
Presentation period 1984-2003.
E.g. Five year (DSS) estimate x% [95% CI].
Period 1984-1993 1994-2003
5 year 53.0 [40.9,65.1] 52.6 [39.2,66.0]
FIGO Stage I II III IV
5 year 75.4 [62.6,88.2] 58.7 [42.0,75.3] 27.7 [9.0,46.5] 22.9 [4.4,41.3]
Morphology SCC AdenoCa Other
5 year 54.8 [45.1,64.5] 24.9 [0.0,54.2] 61.8 [36.8,86.7]
Differentiation Well Moderate Poor Other
5 year 90.9 [73.9,100] 60.7 [43.4,77.9] 44.0 [28.0,60.1] 47.4 [32.5,62.2]
Age ( years ) <40 40-59 60-69 70+
5 year 66.3 [34.4,98.2] 57.6 [40.7,74.5] 56.0 [38.5,73.4] 46.2 [32.2,60.3]
Treatment RT alone Sx alone Sx+RT RT+C
5 year 41.0 [28.4,53.7] 81.3 [62.1,100] 64.0 [44.9,83.0] 49.5 [21.3,77.6]
Vaginal cancer
Page 57
Table 19: Univariate Cox model
Factor DSS RFS
Hazard [95% CI] p-value Hazard [95% CI] p-value
Stage
I vs II 1.65 [0.79,3.4] 0.18 1.44 [0.74,2.8] 0.28
III 4.01 [1.96,8.18] <0.001** 2.79 [1.43,5.4] 0.003**
IV 6.17 [2.9,12.9] <0.001** 4.2 [2.13,8.4] <0.001**
Morphology
SCC vs AdenoCa 1.55 [0.7,3.4] 0.28 1.26 [0.57,2.76] 0.57
Other 0.85 [0.37,2.0] 0.71 0.86 [0.39,1.9] 0.7
Period
1984-1993 vs 1994-2003 0.93 [0.56,1.53] 0.77 0.84 [0.53,1.35] 0.47
Differentiation
Well vs Moderate 5.2 [0.69,38.9] 0.11 2.8 [0.66,12.0] 0.16
Poor 8.7 [1.2,63.6] 0.03* 4.5 [1.09,18.6] 0.04*
Other 7.6 1.04,54.9] 0.05* 4.77 [1.17,19.5] 0.03*
Age
<40 years vs 40-59 1.36 [0.4,4.7] 0.62 1.52 [0.45,5.2] 0.5
60-69 1.4 [0.4,4.9] 0.58 1.94 [0.57,6.57] 0.28
70+ 2.05 [0.63,6.72] 0.23 2.34 [0.7,7.6] 0.16
Treatment
RT vs Sx 0.28 [0.1,0.78] 0.02* 0.54 [0.24,1.2] 0.13
RT+Sx 0.5 [0.24,1.03] 0.06 0.63 [0.3,1.23] 0.17
RT+C 0.72 [0.34,1.55] 0.4 0.8 [0.39,1.7] 0.59
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Table 20: Multivariate Cox model
Factor DSS RFS
Hazard [95% CI] p-value Hazard [95% CI] p-value
Stage
I vs II 1.31 [0.6,2.87] 0.49 1.22 [0.6,2.48] 0.57
III 3.79 [1.66,8.65] 0.002** 2.73 [1.27,5.8] 0.01**
IV 5.14 [2.4,11.0] <0.001** 3.83 [1.87,7.8] <0.001**
Morphology
SCC vs AdenoCa 2.3 [0.9,5.6] 0.07 1.5 [0.64,3.5] 0.35
Other 0.75 [0.26,2.1] 0.58 0.61 [0.22,1.7] 0.34
Period
1984-1993 vs 1994-2003 1.00 [0.51,1.96] 0.99 0.96 [0.51,1.8] 0.89
Differentiation
Well vs Moderate 3.46 [0.45,26.8] 0.23 5.55 [1.26,24.5] 0.02
Poor 6.3 [0.8,49.8] 0.08 3.2 [0.72,14.3] 0.13
Other 6.47 [0.8,49.7] 0.07 3.88 [0.89,16.9] 0.07
Age
<40 years vs 40-59 0.89 [0.23,3.37] 0.86 1.18 [0.32,4.3] 0.8
60-69 1.00 [0.27,3.67] 1.0 1.76 [0.49,6.3] 0.38
70+ 0.95 0.25,3.57] 0.94 1.6 [0.44,5.9] 0.48
Treatment
RT vs Sx 0.4 [0.12,1.33] 0.14 0.89 [0.34,2.34] 0.81
RT+Sx 0.54 [0.22,1.29] 0.16 0.81 [0.36,1.79] 0.6
RT+C 0.65 [0.26,1.6] 0.35 0.96 [0.41,2.24] 0.92
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Figure 54: Overall survival 1984-2003 by FIGO stage
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Figure 55: Relapse free survival 1984-2003 by FIGO stage
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Figure 56: Overall survival 1984-2003 by presentation period
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Figure 57: Relapse free survival 1984-2003 by treatment for relapse
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Figure 58: Overall survival 1984-1993 by FIGO stage
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Figure 59: Overall survival 1994-2003 by FIGO stage
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Figure 60: Relapse free survival 1984-1993 by FIGO stage
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Figure 61: Relapse free survival 1994-2003 by FIGO stage
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Figure 62: Salvage survival 1984-2004 by site of relapse
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Figure 63: Salvage survival 1984-2004 by treatment type for relapse
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Interpretation of results
Table 17 shows the key characteristics of all those patients who were treated for vaginal cancer at QCGC. We have grouped patients into 
two categories based on the year in which they presented (1984 to 1993 and 1994 to 2003). All the key characteristics (age, FIGO staging, 
tumour morphology, and treatment modality) between these two groups were similar, with the exception of tumour grade/differentiation.
Table 18 shows five-year disease specific survival estimates and 95% confidence intervals. Overall 5 year survivals (95% CI) for the 
presentation periods 1984 to 1993 and 1994 to 2003 were 53% (41-65) and 53% (39-66) respectively. These differences were not 
statistically significant. 
Tables 19 and 20 show univariate and multivariate Cox proportional hazards models respectively, evaluating the significance of prognostic 
factors such as age, FIGO stage, treatment time-period, morphology, grade and treatment modality.
Figures 54 and 55 show overall and relapse-free survival between 1984 and 2003, by FIGO stages. Overall survival (95% CI) and relapse-
free survival (95% CI) at 192 months/16 years were 47% (36-57%) and 45% (35-54%) respectively. Figures 56 and 57 show overall and 
relapse-free survival at five years, by presentation period. No significant differences by presentation period could be noticed. Figures 58 to 
61 show overall and relapse-free survival by FIGO stages and by presentation period. Figures 62 and 63 show salvage survival for vaginal 
cancer, by site of relapse and by treatment modality, respectively. The overall salvage survival at five years was 13%.
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Table 21: Patient characteristics
Presentation period 1984-2003 (N=560).
1984-1993 1994-2003
Factor N=196 (%) N=364 (%) p-value
FIGO stage I 78 (40) 176 (48)
II 58 (30) 46 (13)
III 30 (15) 57 (16) <0.001**
IV 19 (10) 27 (7)
Unknown 11 (5) 58 (16)
Morphology SCC 158 (81) 292 (80)
Basal cell 5 (3) 13 (4)
Paget’s disease 5 (3) 22 (6) <0.001**
PigNev 5 (3) 24 (7)
Other 23 (12) 13 (4)
Differentiation Well 49 (25) 82 (23)
Moderate 35 (18) 127 (35) <0.001**
Poor 17 (9) 43 (12)
Other/unknown 95 (48) 112 (31)
Age (years) <30 3 (2) 2 (1)
30-39 15 (8) 24 (7)
40-49 16 (8) 47 (13)
50-59 19 (10) 56 (15) 0.18
60-69 38 (19) 59 (16)
70-79 57 (29) 101 (28)
80+ 48 (24) 75 (21)
Treatment modality Sx alone 149 (76) 287 (79)
RT alone 8 (4) 6 (2)
C alone 0 (0) 0 (0)
Sx+RT 18 (9) 43 (12)
RT+C 10 (5) 8 (2) 0.28
Sx+C 1 (0) 1 (0)
Sx+RT+C 6 (3) 12 (3)
Other 4 (2) 7 (2)
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Table 22: Kaplan and Meier Disease Specific Survival (DSS) estimates and 95% confidence intervals
Presentation Period 1984-2003.
E.g. (5/10/16) year (DSS) estimate x% [95% CI].
Period 1984-1993 1994-2003
5 year 82.3[76.7,87.9] 82.0[77.6,86.4]
10 year 77.1[70.7,83.6] 81.1[76.4,85.8]
16 year 73.5[66.1,80.8] –
FIGO stage I II III IV
5 year 97.0[94.5,99.3] 81.0[73.0,89.0] 62.0[50.2,73.6] 38.0[21.6,54.2]
10 year 90.3[84.5,96.1] 79.5[71.1,87.9] 58.9[46.3,71.4] 37.9[21.6,54.2]
16 year 87.8[80.5,95.2] 70.8[57.1,84.5] – –
Morphology SCC BCC+Paget’s disease PigNev Other
5 year 83.1[79.4,86.9] 94.4[83.9,100] 46.0[22.1,69.9] 78.7[64.5,92.8]
10 year 78.4[73.5,83.3] – – –
16 year 75.6[69.5,81.6] – – 67.4[43.7,91.1]
Differentiation Well Moderate Poor Other
5 year 96.1[92.7,99.5] 80.3[73.6,87.0] 70.8[58.1,83.4] 76.9[70.4,83.4]
10 year 94.2[89.2,99.1] 73.7[69.4,82.5] 67.1[53.2,81.0] 73.8[66.3,81.4]
16 year 83.5[68.5,98.3] – 53.6[27.6,79.7] –
Age (years) <40 40-59 60-69 70+
5 year 92.6[84.5,100.0] 87.9[81.8,94.0] 84.8[77.4,92.2] 76.1[70.6,81.7]
10 year 88.2[76.7,99.6] 82.8[73.5,92.1] 81.0[72.2,89.7] 72.7[66.1,79.3]
16 year – 78.2[65.8,90.6] – 66.1[55.5,76.7]
Treatment RT alone Sx alone Sx+RT RT+C Sx+RT+C
5 year 90.1[87.0,93.2] 42.9[11.7,73.9] 64.7[51.1,78.4] 45.4[21.1,69.8] 48.6[24.8,72.4]
10 year 85.6[91.1,90.1] – – – 24.3[0,60.0]
16 year 84.2[78.9,79.4] – 45.3[20.3,70.4] – –
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Table 23: Univariate Cox model
Factor DSS RFS
Hazard [95% CI] p-value Hazard [95% CI] p-value
Stage
I vs II 3.99 [2.0,7.96] <0.001** 2.61 [1.68,4.06] <0.001**
III 9.44 [4.9,18.2] <0.001** 4.16 [2.66,6.5] <0.001**
IV 20.49 [10.3,40.5] <0.001** 7.65 [4.6,12.6] <0.001**
Morphology
SCC vs BCC 0.34 [0.05,2.39] 0.28 0.61 [0.19,1.9] 0.4
Paget’s disease 0.2 [0.03,1.29] 0.09 1.29 [0.68,2.45] 0.44
PigNev 3.05 [1.66,5.62] <0.001** 2.75 [1.6,4.7] <0.001**
Other 1.18 [0.57,2.45] 0.65 0.96 [0.52,1.77] 0.89
Period
1984-1993 vs 1994-2003 0.94 [0.62,1.42] 0.78 0.94 [0.69,1.29] 0.72
Differentiation
Well vs Moderate 3.83 [1.79,8.2] <0.001** 2.32 [1.4,3.8] <0.001**
Poor 6.41 [2.8,14.7] <0.001** 3.57 [2.0,6.36] <0.001**
Other 3.89 [1.85,8.2] <0.001** 2.53 [1.56,4.08] <0.001**
Age
<40 years vs 40-59 1.5 [0.51,4.4] 0.46 1.24 [0.56,2.7] 0.6
60-69 2.04 [0.69,6.05] 0.2 1.98 [0.9,4.3] 0.08
70+ 3.17 [1.2,8.6] 0.02* 2.63 [1.28,5.4] 0.009**
Treatment
RT vs Sx 0.11 [0.05,0.25] <0.001** 0.21 [0.1,0.43] <0.001**
RT+Sx 0.41 [0.17,0.99] 0.05* 0.54 [0.24,1.18] 0.12
RT+C 0.82 0.31,2.21] 0.7 0.66 [0.25,1.7] 0.39
Sx+RT+C 0.85 [0.32,2.23] 0.73 0.83 [0.33,2.07] 0.7
Other 1.81 [0.66,5.0] 0.25 2.19 [0.82,5.8] 0.12
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Table 24: Multivariate Cox model
Factor DSS RFS
Hazard [95% CI] p-value Hazard [95% CI] p-value
Stage
I vs II 2.92 [1.42,6.04] <0.001** 2.06 [1.29,3.29] <0.001**
III 5.46 [2.5,11.67] <0.001** 2.72 [1.59,4.64] <0.001**
IV 7.48 [3.3,16.9] <0.001** 3.81 [2.07,7.02] <0.001**
Morphology
SCC vs BCC 0.22 [0.03,1.8] 0.28 0.63 [0.18,2.2] 0.47
Paget’s disease 0.13 [0.01,1.2] 0.09 1.6 [0.55,4.6] 0.38
PigNev 1.61 [0.57,4.5] <0.001** 3.29 [1.38,7.87] 0.007**
Other 1.24 [0.55,2.8] 0.65 1.09 [0.56,2.12] 0.8
Period
1984-1993 vs 1994-2003 1.26 [0.79,2.02] 0.78 1.07 [0.76,1.52] 0.69
Differentiation
Well vs Moderate 2.33 [1.05,5.2] <0.001** 1.73 [1.03,2.91] 0.04*
Poor 2.72 [1.14,6.48] <0.001** 2.0 [1.09,3.66] 0.02*
Other 2.96 [1.28,6.8] <0.001** 1.95 [1.13,3.38] 0.02*
Age
<40 years vs 40-59 1.65 [0.54,5.1] 0.46 1.12 [0.51,2.46] 0.79
60-69 1.79 [0.58,5.52] 0.2 1.63 [0.74,3.6] 0.23
70+ 2.47 [0.85,7.2] 0.02* 1.92 [0.92,4.02] 0.08
Treatment
RT vs Sx 0.41 [0.16,1.05] <0.001** 0.55 [0.23,1.27] 0.16
RT+Sx 0.6 [0.24,1.53] 0.05* 0.79 [0.34,1.84] 0.59
RT+C 1.1 [0.39,3.1] 0.7 0.86 [0.32,2.34] 0.76
Sx+RT+C 1.6 [0.56,4.52] 0.73 1.41 [0.54,3.68] 0.49
Other 2.09 [0.64,6.86] 0.25 2.43 [0.83,7.12] 0.1
Vulval cancer
Page 69
Figure 64: Overall survival 1984-2003 by FIGO stage
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Figure 65: Relapse free survival 1984-2003 by FIGO stage
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Figure 66: Overall survival 1984-2003 by presentation period
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Figure 67: Relapse free survival 1984-2003 by presentation period
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Figure 68: Overall survival 1984-1993 by FIGO stage
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Figure 69: Overall survival 1994-2003 by FIGO stage
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98% (176-72) S1
S1  176  156  138  114   91   72  95, 100[  ]
82% (46-18) S2
S2   46   43   39   31   21   18  69,  94[  ]
60% (57-10) S3
S3   57   34   24   16   14   10  46,  73[  ]
45% (27-3) S4
S4   27   14    8    6    3    3  26,  64[  ]  12 months
 95% CI          Median
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Figure 70: Relapse free survival 1984-1993 by FIGO stage
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84% (78-58) S1
S1   78   76   72   65   60   58  76,  92[  ]
56% (58-25) S2
S2   58   46   39   33   28   25  43,  70[  ]
61% (30-11) S3
S3   30   18   16   16   16   11  41,  80[  ]
30% (19-1) S4
S4   19    6    5    3    2    1   5,  54[  ]   9 months
 95% CI           Median
Figure 71: Relapse free survival 1994-2003 by FIGO stage
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86% (176-68) S1
S1  176  154  128  107   86   68  81,  92[  ]
67% (46-16) S2
S2   46   40   36   27   20   16  52,  82[  ]
50% (57-8) S3
S3   57   30   20   12   11    8  36,  64[  ]
41% (27-3) S4
S4   27   11    8    6    3    3  22,  60[  ]  11 months
 95% CI          Median
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Figure 72: Salvage survival 1984-2003 by site of relapse
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47% (124-22) All
 95% CI          Median
  All   124    70    47    38    31    22  37,  57[  ]  37 months
60% (86-21) LR
LR    86    62    42    36    30    21  48,  72[  ]
19% (37-1) Any dist
Any dist    37     8     5     2     1     1   6,  32[  ]   3 months
Figure 73: Salvage survival 1984-2003 by treatment type for relapse
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19% (14-1) RT
 95% CI            Median
RT   14    4    2    2    1    1   0,  41[ ]   6 months
77% (28-11) Sx
Sx   28   24   16   14   12   11  58,  95[ ]
60% (13-3) Sx+RT
Sx+RT   13   12    7    6    6    3  32,  87[ ]
38% (69-7) Other
Other   69   30   22   16   12    7  23,  51[ ]  18 months
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Interpretation of results
Table 21 shows key characteristics of patients diagnosed with vulval cancer by presentation period. Age grouping and treatment modality 
were similar between the two groups. However, there were significant differences in FIGO stages, tumour morphology and differentiation. 
Table 22 shows disease specific survival estimates and 95% confidence intervals. Overall five-year survivals were similar between the 
presentation periods. Tables 23 and 24 show univariate and multivariate Cox proportional hazards models respectively, evaluating the 
significance of prognostic factors such as age, FIGO stage, treatment time-period, morphology, grade and treatment modality.
Figures 64 and 65 show overall and relapse-free survival between 1984 and 2003, by FIGO stages. Overall survival (95% CI) and relapse-
free survival (95% CI) at 192 months/16 years were 74% (69-80%) and 60% (54-65%) respectively. Figures 66 and 67 show overall and 
relapse-free survival at five years by presentation period. Survival curves were similar between the presentation periods. Figures 68-71 
show overall and relapse-free survival by presentation period and FIGO stages. Figures 72 and 73 show five-year salvage survival curves by 
site of relapse and by treatment modality. Between 1982 and 2003, the overall salvage survival (95% CI) at five years was 47% (37-57%).
Appendix 1: Glossary
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AdenoCa adenocarcinoma
AdenoSq adenosquamous carcinoma
Any dist any distant relapse
BCC basal cell carcinoma
C chemotherapy
CI confidence interval
CS carcinosarcoma
DSS disease specific survival
Endometrioid endometrioid adenocarcinoma
FIGO International Federation of Gynecology and Obstetrics
LMS leiomyosarcoma
LR loco-regional relapse
Meso mesodermal mixed tumour
Mucinous mucinous adenocarcinoma
Mull mullerian mixed tumour
PigNev pigmented nevus
QCGC Queensland Centre for Gynaecological Cancer
QCR Queensland Cancer Registry
R radiotherapy
Rel relapse
RFS relapse free survival
RT radiotherapy
S1 stage I
S2 stage II
S3 stage III
S4 stage IV
SCC squamous cell carcinoma
Ser/PapSer serous/papillary serous
Sx surgery
Notes
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